GOSS Stock — Gossamer Bio Inc.: Cash, EV, Pipeline

Share price

$10.73

Market cap

$65.6M

Cash

$57.0M

Enterprise value

$8.6M

Balance sheet

Cash	$57.0M
Debt	$0.0M
Net cash	$57.0M
Enterprise value	$8.6M
Basic shares	488.8M shares
Fully diluted shares	727.3M shares
Fully diluted market cap	$7,804.1M
Cash per share	$0.12

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GOSS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	Seralutinib	Phase 3	Pulmonary Arterial Hypertension	—
Jan 12 - Feb 23	GB002 (seralutinib)	Phase 2	Pulmonary Arterial Hypertension	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

seralutinib

Phase 3 · Active Modality: inhaled small molecule

Aliases GB002

Target PDGFR / CSF1R / c-KIT

Partnerships Pulmokine (in-license; up to $48M development/regulatory milestones, now a XOMA Royalty subsidiary); Chiesi (collaboration terminated July 23, 2026; Gossamer reacquired worldwide rights under Rights Reacquisition Agreement)

Indications

pulmonary arterial hypertension (Stage not disclosed)

Status note Phase 3 PROSERA trial in PAH did not meet its primary endpoint at the prespecified significance threshold. Open-label extension studies remain active.

RT234

Stage not disclosed · Active

Target PDE5

Partnerships Respira Therapeutics (option agreement)

Indications

pulmonary arterial hypertension (Stage not disclosed)
pulmonary hypertension associated with interstitial lung disease (Stage not disclosed)

Catalysts

— None

Status note Complementary on-demand therapeutic opportunity being advanced in a capital-efficient manner under the Respira option agreement.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Seralutinib
Lead indication	Pulmonary Arterial Hypertension
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06274801	Phase 3	Recruiting	Sponsor	GOSS	—	Pulmonary Arterial Hypertension	—
NCT04816604	Phase 2	Active, not recruiting	Sponsor	GOSS	—	Pulmonary Arterial Hypertension	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Gossamer Bio USA, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	212,531	-75,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

GOSS — Gossamer Bio Inc.